Swiss (SMI) Biotech Industry Analysis

Industry Valuation and Performance

Has the Swiss Biotech Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 17 Jun 2026	CHF 1.6b	CHF 348.9m	-CHF 25,736,944.64	211.5x	-60.8x	4.5x
Fri, 15 May 2026	CHF 1.7b	CHF 346.8m	-CHF 15,854,555.22	218.6x	-105.1x	4.8x
Sun, 12 Apr 2026	CHF 1.8b	CHF 347.6m	-CHF 19,468,235.80	254.7x	-92.4x	5.2x
Tue, 10 Mar 2026	CHF 1.9b	CHF 335.7m	-CHF 25,892,000.00	16.1x	-73.6x	5.7x
Thu, 05 Feb 2026	CHF 2.0b	CHF 339.6m	CHF 6.5m	9.7x	310.3x	6x
Sat, 03 Jan 2026	CHF 2.2b	CHF 339.6m	CHF 6.5m	9.3x	331.7x	6.4x
Mon, 01 Dec 2025	CHF 2.0b	CHF 343.6m	-CHF 10,514,000.00	8.3x	-191.4x	5.9x
Wed, 29 Oct 2025	CHF 1.9b	CHF 344.3m	-CHF 15,083,000.00	7.9x	-123.1x	5.4x
Fri, 26 Sep 2025	CHF 1.6b	CHF 344.3m	-CHF 15,083,000.00	7.8x	-105.4x	4.6x
Sun, 24 Aug 2025	CHF 1.9b	CHF 385.0m	-CHF 51,743,000.00	8x	-37.4x	5x
Tue, 22 Jul 2025	CHF 2.1b	CHF 333.9m	-CHF 44,705,000.00	8.5x	-46.2x	6.2x
Thu, 19 Jun 2025	CHF 1.9b	CHF 333.9m	-CHF 44,705,000.00	7.9x	-42.5x	5.7x
Sat, 17 May 2025	CHF 1.8b	CHF 333.9m	-CHF 44,705,000.00	7x	-39.5x	5.3x
Mon, 14 Apr 2025	CHF 1.5b	CHF 411.1m	CHF 65.6m	4.4x	22.1x	3.5x
Wed, 12 Mar 2025	CHF 1.7b	CHF 409.3m	-CHF 35,110,868.00	5x	-47.1x	4x
Fri, 07 Feb 2025	CHF 1.8b	CHF 330.3m	-CHF 75,131,868.00	3.4x	-23.5x	5.3x
Sun, 05 Jan 2025	CHF 1.7b	CHF 330.3m	-CHF 75,131,868.00	2.8x	-22.8x	5.2x
Tue, 03 Dec 2024	CHF 1.6b	CHF 330.9m	-CHF 87,805,465.00	1.6x	-18.4x	4.9x
Thu, 31 Oct 2024	CHF 1.9b	CHF 333.1m	-CHF 82,023,629.00	1.7x	-22.9x	5.6x
Sat, 28 Sep 2024	CHF 1.6b	CHF 333.6m	-CHF 81,088,264.00	1.7x	-19.1x	4.6x
Mon, 26 Aug 2024	CHF 1.4b	CHF 319.7m	-CHF 142,008,264.00	1.9x	-10x	4.4x
Wed, 24 Jul 2024	CHF 759.9m	CHF 151.7m	-CHF 146,197,264.00	1.6x	-5.2x	5x
Fri, 21 Jun 2024	CHF 841.8m	CHF 151.7m	-CHF 146,197,264.00	1.6x	-5.8x	5.5x
Sun, 19 May 2024	CHF 538.2m	CHF 170.3m	-CHF 131,508,021.16	1x	-4.1x	3.2x
Tue, 16 Apr 2024	CHF 443.1m	CHF 67.6m	-CHF 173,113,459.40	0.09x	-2.6x	6.6x
Thu, 14 Mar 2024	CHF 338.4m	CHF 55.5m	-CHF 173,248,004.84	0.3x	-2x	6.1x
Sat, 10 Feb 2024	CHF 370.6m	CHF 55.4m	-CHF 173,281,198.02	1x	-2.1x	6.7x
Mon, 08 Jan 2024	CHF 324.0m	CHF 317.4m	-CHF 176,097,332.00	0.5x	-1.8x	1x
Wed, 06 Dec 2023	CHF 341.7m	CHF 317.9m	-CHF 209,011,437.00	n/a	-1.6x	1.1x
Fri, 03 Nov 2023	CHF 258.1m	CHF 318.6m	-CHF 211,390,599.00	n/a	-1.2x	0.8x
Sun, 01 Oct 2023	CHF 262.4m	CHF 318.6m	-CHF 213,557,748.00	n/a	-1.2x	0.8x
Tue, 29 Aug 2023	CHF 301.3m	CHF 318.7m	-CHF 188,662,518.00	n/a	-1.6x	0.9x
Thu, 27 Jul 2023	CHF 338.4m	CHF 320.3m	-CHF 179,711,882.00	n/a	-1.9x	1.1x
Sat, 24 Jun 2023	CHF 306.0m	CHF 331.2m	-CHF 180,872,814.00	n/a	-1.7x	0.9x

Current Industry PE

Investors are relatively neutral on the Swiss Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.

The industry is trading close to its 3-year average PS ratio of 4.3x.

Past Earnings Growth

The earnings for companies in the Biotechs industry have improved over the last three years.
Meanwhile revenues have remained mostly flat.
This means that companies overall are more efficiently conducting business since losses are shrinking while sales have been flat.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?


CH Market	2.62%
Healthcare	0.98%
Biotech	1.18%
Biotech	1.18%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Company	Last Price	7D	1Y	Valuation
IDIA Idorsia	CHF 4.65	6.2% +CHF 68.9m	131.3%	PS5.4x
BSLN Basilea Pharmaceutica	CHF 50.40	3.7% +CHF 22.3m	0.4%	PE15.5x
MOLN Molecular Partners	CHF 3.13	2.3% +CHF 2.6m	1.0%	PB1.7x

Company

Last Price

Valuation

IDIA Idorsia

CHF 4.65

6.2%
+CHF 68.9m

131.3%

PS5.4x

BSLN Basilea Pharmaceutica

CHF 50.40

3.7%
+CHF 22.3m

0.4%

PE15.5x

MOLN Molecular Partners

CHF 3.13

2.3%
+CHF 2.6m

1.0%

PB1.7x

Basilea Pharmaceutica Ltd Receives Additional USD 13.3 Million From BARDA To Continue Development Of Novel Antibiotic Ceftibuten-Ledaborbactam Etzadroxil

Basilea Pharmaceutica Ltd, Allschwil announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD 13.3 million to Basilea to continue the development of Basilea’s novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. After the current tranche of USD 13.3 million, a total of USD 25 million have been committed by BARDA. The contract could provide up to USD 133 million of additional non-dilutive funding. Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections caused by multidrug-resistant bacterial pathogens. Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales. Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use. Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options. Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48).

Swiss (SMI) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Idorsia Ltd announced that it expects to receive CHF 250 million in funding

New minor risk - Shareholder dilution

Kuros Biosciences Targets US$300 Million Sales by 2028 With Executive Team Realignment

MindMaze Therapeutics Holding SA, Annual General Meeting, Jun 25, 2026

Basilea Pharmaceutica Ltd Receives Additional USD 13.3 Million From BARDA To Continue Development Of Novel Antibiotic Ceftibuten-Ledaborbactam Etzadroxil

High number of new directors